![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Moderna in Talks With NIH Over COVID-19 Vaccine Patent Dispute
Moderna in Talks With NIH Over COVID-19 Vaccine Patent Dispute
November 17, 2021
Moderna and the National Institutes of Health (NIH) are working to resolve a patent dispute over who created the messenger RNA-based substance used in the company’s COVID-19 vaccine.
Moderna disagreed that NIH scientists helped co-invent the mRNA sequence, but now says it is willing to make the government “co-owners of those patent applications that only listed Moderna scientists as inventors.” As a co-owner, the government will have the right to license the patent.
The Moderna-NIH COVID-19 vaccine partnership was the result of a four-year collaboration originally meant to develop vaccines for several other diseases, such as Middle East respiratory syndrome.
Upcoming Events
-
21Oct